Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine
Fig 6
Activated T-cells (ACD4 + ACD8) when optimal (blue and green solid curves, respectively) and suboptimal (dashed, solid and dotted orange are 3, 1, 0.1 folds of clinical trial dose, respectively) vaccine doses are applied to each patient using J1 and J2. Red dots represent patients’ measurements at specific times in the clinical trial with 15% standard error. The vertical green dashed lines correspond to the days of vaccination.